Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of “Moderate Buy” by Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $31.3333.

A number of equities research analysts have issued reports on the company. Zacks Research lowered Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. TD Cowen reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $31.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th.

Insider Transactions at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the transaction, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. This represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Monte Rosa Therapeutics by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock valued at $18,896,000 after purchasing an additional 53,278 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Monte Rosa Therapeutics by 11.8% in the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after buying an additional 1,199 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $172,000. Strs Ohio purchased a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $566,000. Finally, Vanguard Group Inc. raised its stake in Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after acquiring an additional 257,547 shares in the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Stock Up 0.2%

Shares of GLUE stock opened at $19.59 on Thursday. The firm has a 50 day moving average of $19.36 and a two-hundred day moving average of $12.32. The stock has a market capitalization of $1.28 billion, a PE ratio of 61.22 and a beta of 1.61. Monte Rosa Therapeutics has a 52 week low of $3.50 and a 52 week high of $25.77.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.